ZTS — Bearish (ASignal Rank 4/4)
ASignal's 10+ AI agent pipeline rates ZTS as Bearish with 75% confidence in the Healthcare sector.
AI Analysis Summary
Zoetis (ZTS) presents significant downside risk due to extreme leverage, overvaluation, and bearish technicals. Target price of $100.31 suggests ~15% downside potential.
Investment Framework Assessment
Evaluated through three legendary investor frameworks:
- Warren Buffett (Value Investing): Grade D — 35/100
- Bill Ackman (Activist Investing): Grade B — 60/100
- Ray Dalio (Macro/Risk Parity): Grade C — 55/100
Consensus: Bearish
Price Intelligence
- Current price: $117.87
- Price target: $102.44 (-13.1%)
- Risk level: high
- Horizon: medium term
Quality Assessment
- Balance sheet: concerning
- Cash flow: good
- Competitive moat: none
Peer Group Analysis
ZTS is in the “Oversold & Compressed” cluster alongside ZBH, XOM, WFC, WDAY, VLO (128 stocks total). 0 of 128 peers are currently bullish.